Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.52 |
| ▸ | F7 | P08709 | 8/20 | 0.52 |
| ▸ | F2 | P00734 | 8/20 | 0.49 |
| ▸ | TMPRSS6 | Q8IU80 | 3/20 | 0.49 |
| ▸ | F10 | P00742 | 2/20 | 0.49 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
| ▸ | MASP2 | O00187 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 2/20 | 0.42 |
| ▸ | PROC | P04070 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15289767 | 0.82 | F7 (0.57) | ST14F7F2TMPRSS6F10 | |
| SCHEMBL12514173 | 0.80 | TMPRSS6 (0.48) | ST14F7F2TMPRSS6F10 | |
| SCHEMBL8290747 | 0.79 | F7 (0.60) | ST14F7F2TMPRSS6F10 | |
| Hydrochloric Acid SCHEMBL6366354 | 0.78 | F7 (0.44) | ST14F7F2TMPRSS6F10 | |
| SCHEMBL8345186 | 0.76 | F2 (0.51) | F2TMPRSS6F10PROCADRA1B | |
| SCHEMBL8345195 | 0.76 | F2 (0.49) | ST14F7F2TMPRSS6F10 | |
| SCHEMBL8346530 | 0.76 | F2 (0.57) | F2TMPRSS6F10ADRA1BPRSS1 | |
| Hydrochloric Acid SCHEMBL6370372 | 0.76 | F7 (0.42) | ST14F7F2TMPRSS6F10 | |
| SCHEMBL5685819 | 0.76 | ST14 (0.58) | ST14F7F2TPSAB1MASP2 | |
| SCHEMBL7118946 | 0.75 | MEN1 (0.53) | F7F2F10PROCADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | ST14 160/4885F7 3556/4885F2 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.